Vimarsana
Biggest News Aggregation in the World

Page 10 - Deric Dube News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deric Dube. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deric Dube Today - Breaking & Trending Today

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand - Vimarsana News

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Vifor Pharma Group: Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand - Vimarsana News

Vifor Pharma Group: Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)

07.19.21 -- First-Time CEO Transforms Retrophin Into Travere - Vimarsana News

07.19.21 -- First-Time CEO Transforms Retrophin Into Travere

07.19.21 -- First-Time CEO Transforms Retrophin Into Travere   On this week's episode of the Business of Biotech, Diamyd Medical President & CEO Dr. Ulf Hannelius talks about developing therapies aimed at preserving and restoring insulin production in Type 1 diabetes patients, plus the why and the how behind the company's choice to manufacture them in-house. Listen now and subscribe so you never miss an episode. Articles   Eric Dube, Ph.D., was dubious when an executive recruiter pitched him the CEO position at previously embattled Retrophin (remember Mart...

FDA sets back Travere's plans for kidney disease drug approval - Vimarsana News

FDA sets back Travere's plans for kidney disease drug approval

The FDA has crushed Travere Therapeutics’ hopes of seeking accelerated approval in a rare kidney disorder on the strength of existing interim data from a phase 3 clinical trial. Travere said it may have enough data to meet the FDA’s demands by the first half of next year.

Why Travere Therapeutics Stock Is Plummeting Today - Vimarsana News

Why Travere Therapeutics Stock Is Plummeting Today

Author Bio Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles. What happened The stock of Travere Therapeutics (NASDAQ:TVTX) was on the decline by almost 17% in midafternoon trading Wednesday. That was on the back of dispiriting regulatory news from the rare-disease biotech. So what Travere disclosed that t...

Source: fool.com